This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Masimo (MASI) Down 1.5% Since the Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ride Out MedTech Volatility With These 3 Ultra-Safe Stocks
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these three low-beta MedTech stocks stand out as the most suitable value picks.
3 Excellent Value Picks as Political Chaos Grips MedTech
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these three MedTech stocks stand out as the most suitable value picks.
Zacks.com featured highlights: CBRE Group, East West Bancorp, Hasbro, Canadian Pacific Railway and Masimo
by Zacks Equity Research
Zacks.com featured highlights: CBRE Group, East West Bancorp, Hasbro, Canadian Pacific Railway and Masimo
5 GARP Stocks to Buy for Marvelous Returns
by Zacks Equity Research
GARP helps an investor gain exposure to stocks that are undervalued and have impressive prospects.
Here's Why Chemed (CHE) is a Suitable Growth Pick for Now
by Zacks Equity Research
Banking on favorable Net Margin and ROE, Chemed (CHE) stands out as one of the most suitable growth stocks.
IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why
by Zacks Equity Research
Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.
Is Amedisys (AMED) a Great Value Stock for Your Portfolio?
by Zacks Equity Research
Banking on a number of favorable metrics, Amedisys (AMED) stands out as one of the most suitable value stock.
Here's Why Masimo (MASI) is a Suitable Value Pick for Now
by Zacks Equity Research
Masimo (MASI) seems to be a solid value pick with favorable P/E ratio and P/FCF ratio compared with its broader industry.
McKesson Banks on Distribution Business Amid Pricing Woes
by Zacks Equity Research
McKesson (MCK) entered fiscal 2018 with an assumption of branded inflation in the mid-single digits. Pricing pressure in the independent retail pharmacy channel is a headwind.
BioTelemetry Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
BioTelemetry (BEAT) is putting efforts in product innovation through research and development. The company recently announced the acquisition of LifeWatch AG in a deal valued at about $280 million.
Masimo (MASI) Introduces SafetyNet System in Dubai Hospitals
by Zacks Equity Research
Masimo's (MASI) proprietary Patient SafetyNet system's introduction in the Dubai market is in line with its strategy of becoming the dominant player in the pulse oximetry market.
Zacks.com featured highlights: CBRE Group, Canadian Pacific Railway, East West Bancorp, Hasbro and Masimo
by Zacks Equity Research
Zacks.com featured highlights: CBRE Group, Canadian Pacific Railway, East West Bancorp, Hasbro and Masimo
Top 5 GARP Stocks to Scoop Up Right Now
by Zacks Equity Research
The GARP approach prefers stocks that are priced below the market or any reasonable target determined by fundamental analysis.
Masimo (MASI) Beats on Q2 Earnings and Revenues, Guides Up
by Zacks Equity Research
Masimo's (MASI) stable performance across its businesses was the key highlight of second quarter.
MedTech Stock Earnings Slated for Aug 2: CAH, HOLX & More
by Zacks Equity Research
Despite solid strategic initiatives, the ongoing political conundrum at the Capitol Hill is likely to affect earnings results of these four major Medical Technology bigwigs.
Masimo (MASI) Rainbow Super DCI-mini Sensor Now CE Marked
by Zacks Equity Research
Irvine, CA-based Masimo Corporation (MASI) recently announced the receipt of CE mark for the noninvasive and reusable rainbow Super DCI-mini sensor.
Masimo (MASI) Presents Utility Study of Oxygen Reserve Index
by Zacks Equity Research
Masimo Corporation (MASI) recently announced data from its study evaluating the potential clinical utility of Masimo Oxygen Reserve Index.
Zacks.com featured highlights: 58.com, RPC, U.S. Silica Holdings, Masimo and Manitowoc
by Zacks Equity Research
Zacks.com featured highlights: 58.com, RPC, U.S. Silica Holdings, Masimo and Manitowoc
5 Stocks to Watch for Accelerating Earnings Growth
by Tirthankar Chakraborty
Earnings acceleration should be viewed as a key metric for share price outperformance
Masimo (MASI) O3 Regional Oximetry Device Gets FDA Nod
by Zacks Equity Research
Masimo Corporation (MASI) recently announced the receipt of FDA 510(k) clearance for O3 regional oximetry device.
Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up
by Zacks Equity Research
Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.
Zacks.com featured highlights: Ituran Location and Control, Molina Healthcare, WellCare Health Plans and Masimo
by Zacks Equity Research
Zacks.com featured highlights: Ituran Location and Control, Molina Healthcare, WellCare Health Plans and Masimo
4 Top-Ranked Liquid Stocks for a Winning Portfolio
by Zacks Equity Research
Liquidity of a stock primarily indicates a company's capability to meet debt obligations by converting assets into liquid cash and equivalents.
After ISRG Q1 Earnings, 3 Medical Instrument Stocks Looking Up
by Zacks Equity Research
While the Medical Instrument industry has been oscillating between hope and despair, let us take a look at three stocks which are expected to put up an impressive show this earnings season like Intuitive Surgical.